TTLL7

Summary

TTLL7 (tubulin tyrosine ligase like 7, HGNC:26242) is a protein-coding gene on chromosome 1p31.1, encoding Tubulin polyglutamylase TTLL7 (Q6ZT98). Polyglutamylase which modifies tubulin, generating polyglutamate side chains of variable lengths on the gamma-carboxyl group of specific glutamate residues within the C-terminal tail of tubulin.

Enables alpha-tubulin binding activity; beta-tubulin binding activity; and tubulin-glutamic acid ligase activity. Involved in protein polyglutamylation. Predicted to be located in 9+0 non-motile cilium. Predicted to be active in ciliary basal body.

Source: NCBI Gene 79739 — RefSeq curated summary.

At a glance

• GWAS associations: 13
• Clinical variants (ClinVar): 100 total
• MANE Select transcript: NM_024686

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26242
Approved symbol	TTLL7
Name	tubulin tyrosine ligase like 7
Location	1p31.1
Locus type	gene with protein product
Status	Approved
Aliases	FLJ23033
Ensembl gene	ENSG00000137941
Ensembl biotype	protein_coding
OMIM	618813
Entrez	79739

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 9 protein_coding_CDS_not_defined, 4 protein_coding, 3 nonsense_mediated_decay

ENST00000260505, ENST00000464289, ENST00000467670, ENST00000472688, ENST00000472937, ENST00000474702, ENST00000474957, ENST00000477524, ENST00000480174, ENST00000480533, ENST00000482783, ENST00000485638, ENST00000488014, ENST00000610996, ENST00000865825, ENST00000865826

RefSeq mRNA: 3 — MANE Select: NM_024686 NM_001350214, NM_001350215, NM_024686

CCDS: CCDS690

Canonical transcript exons

ENST00000260505 — 21 exons

Exon	Start	End
ENSE00001932342	83998931	83999132
ENSE00003466131	83951845	83951976
ENSE00003468184	83929136	83929230
ENSE00003468796	83917604	83917690
ENSE00003489651	83907456	83907661
ENSE00003495701	83890321	83890481
ENSE00003508224	83919699	83919834
ENSE00003521378	83882963	83883136
ENSE00003531455	83921087	83921160
ENSE00003536086	83942463	83942679
ENSE00003568295	83937852	83938016
ENSE00003572029	83949865	83949986
ENSE00003575975	83904079	83904159
ENSE00003582668	83911165	83911363
ENSE00003591056	83947124	83947282
ENSE00003613828	83952187	83952387
ENSE00003624541	83921247	83921394
ENSE00003647112	83906329	83906463
ENSE00003650528	83865024	83870082
ENSE00003663958	83948628	83948695
ENSE00003682038	83933608	83933766

Expression profiles

Bgee: expression breadth ubiquitous, 234 present calls, max score 97.81.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 19.8280 / max 726.3804, expressed in 1356 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
12970	19.6926	1354
12967	0.0799	18
12968	0.0555	28

Top tissues by expression

285 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
corpus callosum	UBERON:0002336	97.81	gold quality
endothelial cell	CL:0000115	97.71	gold quality
Brodmann (1909) area 23	UBERON:0013554	96.05	gold quality
postcentral gyrus	UBERON:0002581	95.16	gold quality
middle temporal gyrus	UBERON:0002771	94.83	gold quality
inferior vagus X ganglion	UBERON:0005363	94.46	gold quality
primary visual cortex	UBERON:0002436	94.32	gold quality
parietal lobe	UBERON:0001872	94.10	gold quality
subthalamic nucleus	UBERON:0001906	93.67	gold quality
lateral globus pallidus	UBERON:0002476	93.42	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	93.35	gold quality
pons	UBERON:0000988	93.14	gold quality
superior frontal gyrus	UBERON:0002661	93.03	gold quality
right coronary artery	UBERON:0001625	93.01	gold quality
occipital lobe	UBERON:0002021	92.90	gold quality
substantia nigra pars reticulata	UBERON:0001966	92.59	gold quality
Ammon’s horn	UBERON:0001954	92.56	gold quality
globus pallidus	UBERON:0001875	92.43	gold quality
spinal cord	UBERON:0002240	92.38	gold quality
entorhinal cortex	UBERON:0002728	92.34	gold quality
popliteal artery	UBERON:0002250	92.21	gold quality
tibial artery	UBERON:0007610	92.19	gold quality
medial globus pallidus	UBERON:0002477	91.96	gold quality
aorta	UBERON:0000947	91.88	gold quality
blood vessel layer	UBERON:0004797	91.67	gold quality
thoracic aorta	UBERON:0001515	91.56	gold quality
ascending aorta	UBERON:0001496	91.51	gold quality
prefrontal cortex	UBERON:0000451	91.39	gold quality
cortical plate	UBERON:0005343	91.27	gold quality
descending thoracic aorta	UBERON:0002345	91.24	gold quality

Single-cell (SCXA)

Detected in 6 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-HCAD-35	yes	2872.32
E-HCAD-25	yes	51.93
E-GEOD-84465	yes	12.03
E-HCAD-11	yes	7.64
E-ANND-3	yes	6.34
E-GEOD-180759	no	2084.54

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

81 targeting TTLL7, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-545-3P	99.95	70.74	2783
HSA-MIR-141-3P	99.94	72.79	2421

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	ttll7	ENSDARG00000062973
mus_musculus	Ttll7	ENSMUSG00000036745
rattus_norvegicus	Ttll7	ENSRNOG00000031997

Paralogs (12): TTLL1 (ENSG00000100271), TTLL12 (ENSG00000100304), TTLL2 (ENSG00000120440), TTLL9 (ENSG00000131044), TTLL4 (ENSG00000135912), TTLL8 (ENSG00000138892), TTLL10 (ENSG00000162571), TTLL6 (ENSG00000170703), TTLL11 (ENSG00000175764), KPRP (ENSG00000203786), TTLL13 (ENSG00000213471), TTLL3 (ENSG00000214021)

Protein

Protein identifiers

Tubulin polyglutamylase TTLL7 — Q6ZT98 (reviewed: Q6ZT98)

Alternative names: Testis development protein NYD-SP30, Tubulin–tyrosine ligase-like protein 7

All UniProt accessions (4): Q6ZT98, A0A087X234, F2Z2J7, F2Z2X2

UniProt curated annotations — full annotation on UniProt →

Function. Polyglutamylase which modifies tubulin, generating polyglutamate side chains of variable lengths on the gamma-carboxyl group of specific glutamate residues within the C-terminal tail of tubulin. Mediates both ATP-dependent initiation and elongation steps of the polyglutamylation reaction. Preferentially modifies the beta-tubulin tail over an alpha-tail. Competes with monoglycylase TTLL3 for modification site on beta-tubulin substrate, thereby creating an anticorrelation between glycylation and glutamylation reactions. Required for neurite growth; responsible for the strong increase in tubulin polyglutamylation during postnatal neuronal maturation.

Subunit / interactions. Interacts with both alpha- and beta-tubulin (via C-terminal tubulin tails).

Subcellular location. Cell projection. Cilium. Cytoplasm. Cytoskeleton. Cilium basal body. Dendrite. Perikaryon.

Tissue specificity. Highly expressed in the nervous system including spinal cord, thalamus, hippocampus, hypothalamus and cerebellum.

Domain organisation. The enzyme uses its core to engage the disordered anionic tails of alpha- and beta-tubulin and the flexible c-MTBD (cationic microtubule binding domain) region to bind the microtubule and position itself for beta-tail modification. The c-MTBD region is positively charged and becomes ordered when bound to microtubules: it interacts with a negatively charged patch on alpha-tubulin. The presence of positive charges in the c-MTBD region is essential for proper binding.

Similarity. Belongs to the tubulin–tyrosine ligase family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q6ZT98-1	1	yes
Q6ZT98-2	2
Q6ZT98-3	3

RefSeq proteins (3): NP_001337143, NP_001337144, NP_078962* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR004344	TTL/TTLL_fam	Family

Pfam: PF03133

Enzyme classification (BRENDA):

• EC 6.3.2.B24 — (BRENDA: organisms, substrates, inhibitors, Km, kcat entries)

Catalyzed reactions (Rhea), 2 shown:

• L-glutamyl-[protein] + L-glutamate + ATP = gamma-L-glutamyl-L-glutamyl-[protein] + ADP + phosphate + H(+) (RHEA:60144)
• (L-glutamyl)(n)-gamma-L-glutamyl-L-glutamyl-[protein] + L-glutamate + ATP = (L-glutamyl)(n+1)-gamma-L-glutamyl-L-glutamyl-[protein] + ADP + phosphate + H(+) (RHEA:60148)

UniProt features (77 total): strand 15, binding site 14, mutagenesis site 12, helix 9, sequence conflict 8, region of interest 4, splice variant 4, turn 4, compositionally biased region 3, site 2, chain 1, domain 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
4YLR	X-RAY DIFFRACTION	2.55
4YLS	X-RAY DIFFRACTION	2.6

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6ZT98-F1	72.54	0.34

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2): 106 (binds negatively charged residues of beta-tubulin c-terminal tails); 352 (binds negatively charged residues of beta-tubulin c-terminal tails)

Ligand- & substrate-binding residues (14): 166–167; 188–191; 201–203; 227; 249–250; 251; 252; 271; 336; 349; 349; 351 …

Mutagenesis-validated functional residues (12):

Position	Phenotype
106	nearly abolished polyglutamylase activity.
143–146	70% decreased polyglutamylase activity.
178	decreased polyglutamylase activity.
205	nearly abolished polyglutamylase activity.
227	nearly abolished polyglutamylase activity.
271	nearly abolished polyglutamylase activity.
349	loss of polyglutamylase activity.
352	nearly abolished polyglutamylase activity.
385–393	45% decreased binding to microtubules. decreased polyglutamylase activity. 76% decreased binding to microtubules; when a
425–427	76% decreased binding to microtubules; when associated with 385-e–e-393.
477–480	40% decreased polyglutamylase activity.
490–500	69% decreased polyglutamylase activity.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-8955332	Carboxyterminal post-translational modifications of tubulin

MSigDB gene sets: 162 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_TUMORAL_MACROPHAGE_UP, BENPORATH_ES_WITH_H3K27ME3, FISCHER_G1_S_CELL_CYCLE, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, CAGCTG_AP4_Q5, GOCC_MICROTUBULE_ORGANIZING_CENTER, LIAO_METASTASIS, TGANTCA_AP1_C, GOBP_PEPTIDYL_GLUTAMIC_ACID_MODIFICATION, GOMF_LIGASE_ACTIVITY_FORMING_CARBON_NITROGEN_BONDS, GOMF_ACID_AMINO_ACID_LIGASE_ACTIVITY, LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN, TGTTTAC_MIR30A5P_MIR30C_MIR30D_MIR30B_MIR30E5P, GOCC_NEURON_PROJECTION, CUI_TCF21_TARGETS_2_DN

GO Biological Process (5): microtubule cytoskeleton organization (GO:0000226), nervous system development (GO:0007399), protein polyglutamylation (GO:0018095), cell differentiation (GO:0030154), protein modification process (GO:0036211)

GO Molecular Function (10): ATP binding (GO:0005524), tubulin binding (GO:0015631), alpha-tubulin binding (GO:0043014), metal ion binding (GO:0046872), beta-tubulin binding (GO:0048487), tubulin-glutamic acid ligase activity (GO:0070740), protein-glutamic acid ligase activity, initiating (GO:0106437), protein-glutamic acid ligase activity, elongating (GO:0106438), nucleotide binding (GO:0000166), ligase activity (GO:0016874)

GO Cellular Component (9): cytosol (GO:0005829), microtubule (GO:0005874), dendrite (GO:0030425), ciliary basal body (GO:0036064), perikaryon (GO:0043204), cytoplasm (GO:0005737), cytoskeleton (GO:0005856), cilium (GO:0005929), cell projection (GO:0042995)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Post-translational protein modification	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
protein-glutamic acid ligase activity	3
tubulin binding	2
cytoskeleton organization	1
microtubule-based process	1
system development	1
peptidyl-glutamic acid modification	1
cellular developmental process	1
protein metabolic process	1
macromolecule modification	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
cytoskeletal protein binding	1
cation binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
catalytic activity	1
cytoplasm	1
microtubule cytoskeleton	1
polymeric cytoskeletal fiber	1
neuron projection	1
dendritic tree	1
microtubule organizing center	1
cilium	1
neuronal cell body	1
intracellular anatomical structure	1
intracellular membraneless organelle	1
intraciliary transport particle	1
membrane-bounded organelle	1
plasma membrane bounded cell projection	1

Protein interactions and networks

STRING

598 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TTLL7	TTLL3	Q9Y4R7	596
TTLL7	AGBL4	Q5VU57	531
TTLL7	CPXM2	Q8N436	505
TTLL7	TTLL5	Q6EMB2	501
TTLL7	ATAT1	Q5SQI0	496
TTLL7	SVBP	Q8N300	482
TTLL7	ZNF142	P52746	461
TTLL7	DRC8	Q5VUJ9	457
TTLL7	SPAST	Q9UBP0	447
TTLL7	AGTPBP1	Q9UPW5	440
TTLL7	WDR64	B1ANS9	433
TTLL7	DYNC1I1	O14576	433
TTLL7	AGBL5	Q8NDL9	431
TTLL7	PLEKHG1	Q9ULL1	431
TTLL7	HECW1	Q76N89	424

IntAct

10 interactions, top by confidence:

A	B	Type	Score
YWHAH	PLEKHG3	psi-mi:“MI:0914”(association)	0.610
TTLL7	ANXA2	psi-mi:“MI:0915”(physical association)	0.400
MEF2A	REV3L	psi-mi:“MI:0914”(association)	0.350
CUL4B	APBB1	psi-mi:“MI:0914”(association)	0.350
YWHAG	C1orf226	psi-mi:“MI:0914”(association)	0.350
YWHAE	DEPDC5	psi-mi:“MI:0914”(association)	0.350
YWHAG	FOXO6	psi-mi:“MI:0914”(association)	0.350
TTLL7	CSNK2A2	psi-mi:“MI:0914”(association)	0.350
	EBAG9	psi-mi:“MI:0914”(association)	0.350

BioGRID (19): TTLL7 (Two-hybrid), TTLL7 (Reconstituted Complex), TTLL7 (Affinity Capture-MS), CSNK2A2 (Affinity Capture-MS), ZMYM1 (Affinity Capture-MS), CSNK2A1 (Affinity Capture-MS), TTLL7 (Affinity Capture-RNA), LMO4 (Two-hybrid), TTLL7 (Proximity Label-MS), ZMYM1 (Affinity Capture-MS), CSNK2A1 (Affinity Capture-MS), CSNK2A2 (Affinity Capture-MS), TTLL7 (Affinity Capture-MS), YWHAH (Affinity Capture-MS), TTLL7 (Affinity Capture-MS)

ESM2 similar proteins: A2AD83, A4Q9F0, A6QP06, A7KAX9, B2RYE5, B4K6T8, F7E540, G5EEW9, O00443, O13839, O43283, O96838, P11171, P11434, P48193, Q12923, Q14693, Q22744, Q3V0G7, Q5FVG2, Q5R8N8, Q5R8X7, Q5RAY1, Q61194, Q64512, Q6DTM3, Q6GPD0, Q6Q7P4, Q6ZT98, Q6ZUT3, Q811P8, Q8BGS1, Q8BPQ7, Q8CHB8, Q8K3Y6, Q8WYB5, Q91573, Q91ZP3, Q96HH9, Q99PI5

Diamond homologs: A2APC3, A4Q9E4, A4Q9E5, A4Q9E8, A4Q9F0, A4Q9F1, A4Q9F4, A4Q9F6, A6NNM8, A6PVC2, A8CVX7, A8X9V4, B2GUB3, E9P886, F7E540, H2KZM9, O95922, P38160, P38584, Q09647, Q0VC71, Q14679, Q1ECV4, Q23AS2, Q23K29, Q23MT7, Q23SI8, Q3SXZ7, Q3SZH6, Q564U4, Q5PPI9, Q5R978, Q641W7, Q6EEF3, Q6EMB2, Q6ZT98, Q80UG8, Q8CHB8, Q8N841, Q8NG68

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

100 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	91
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

4392 predictions. Top by Δscore:

Variant	Effect	Δscore
1:83890319:A:AC	donor_gain	1.0000
1:83890319:AC:A	donor_gain	1.0000
1:83890320:C:CC	donor_gain	1.0000
1:83890320:CC:C	donor_gain	1.0000
1:83902152:A:AC	donor_gain	1.0000
1:83902153:C:CC	donor_gain	1.0000
1:83904070:ATTAC:A	donor_loss	1.0000
1:83904071:TTACT:T	donor_loss	1.0000
1:83904072:TAC:T	donor_loss	1.0000
1:83904073:AC:A	donor_loss	1.0000
1:83904075:T:TA	donor_loss	1.0000
1:83904076:CACT:C	donor_loss	1.0000
1:83904077:A:AC	donor_gain	1.0000
1:83904077:ACTTT:A	donor_loss	1.0000
1:83904078:C:CC	donor_gain	1.0000
1:83904078:CTTTT:C	donor_gain	1.0000
1:83906323:A:AC	donor_gain	1.0000
1:83906323:ACTC:A	donor_loss	1.0000
1:83906324:C:CC	donor_gain	1.0000
1:83906324:CTCA:C	donor_gain	1.0000
1:83906325:TCACA:T	donor_loss	1.0000
1:83906326:CACAT:C	donor_loss	1.0000
1:83906327:A:AC	donor_gain	1.0000
1:83906327:ACAT:A	donor_gain	1.0000
1:83906328:C:CC	donor_gain	1.0000
1:83906328:C:CG	donor_loss	1.0000
1:83906328:CA:C	donor_gain	1.0000
1:83906328:CAT:C	donor_gain	1.0000
1:83906328:CATC:C	donor_gain	1.0000
1:83906328:CATCT:C	donor_gain	1.0000

AlphaMissense

5847 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:83929177:T:A	K367N	1.000
1:83929177:T:G	K367N	1.000
1:83929178:T:A	K367I	1.000
1:83929213:G:C	S355R	1.000
1:83929213:G:T	S355R	1.000
1:83929215:T:G	S355R	1.000
1:83929217:G:C	P354R	1.000
1:83929217:G:T	P354Q	1.000
1:83929225:G:C	N351K	1.000
1:83929225:G:T	N351K	1.000
1:83929227:T:C	N351D	1.000
1:83933608:C:A	E349D	1.000
1:83933608:C:G	E349D	1.000
1:83933609:T:A	E349V	1.000
1:83933609:T:G	E349A	1.000
1:83933610:C:T	E349K	1.000
1:83933612:A:G	L348P	1.000
1:83933615:A:T	L347H	1.000
1:83933647:A:C	D336E	1.000
1:83933647:A:T	D336E	1.000
1:83933648:T:A	D336V	1.000
1:83933648:T:C	D336G	1.000
1:83933648:T:G	D336A	1.000
1:83933649:C:G	D336H	1.000
1:83933654:C:T	G334E	1.000
1:83933655:C:G	G334R	1.000
1:83933655:C:T	G334R	1.000
1:83933657:A:G	L333P	1.000
1:83933668:G:C	C329W	1.000
1:83933726:A:T	V310D	1.000

dbSNP variants (sampled 300 via entrez): RS1000031122 (1:83931478 C>T), RS1000079438 (1:83877421 G>A), RS1000085318 (1:83884868 T>TACA), RS1000088210 (1:83898398 T>A), RS1000150735 (1:83986647 C>A,T), RS1000170868 (1:83911182 T>C), RS1000182287 (1:83986477 G>A), RS1000182349 (1:83942157 T>C,G), RS1000191589 (1:83893247 T>G), RS1000230596 (1:83927863 T>C,G), RS1000312786 (1:83935310 T>C), RS1000321924 (1:83871449 G>A,C), RS1000323936 (1:83934822 G>C,T), RS1000357801 (1:83981157 C>A), RS1000395564 (1:83967766 T>C)

Disease associations

OMIM: gene MIM:618813 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

13 associations (top):

Study	Trait	p-value
GCST000484_2	Alzheimer’s disease	1.000000e-06
GCST001692_14	Response to taxane treatment (docetaxel)	2.000000e-06
GCST001762_457	Obesity-related traits	7.000000e-06
GCST001762_464	Obesity-related traits	8.000000e-06
GCST002671_1	Toenail selenium levels	9.000000e-06
GCST002783_42	Body mass index	2.000000e-06
GCST003124_13	Mild influenza (H1N1) infection	1.000000e-09
GCST006069_68	Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)	2.000000e-06
GCST006073_10	Tenofovir clearance in HIV infection	8.000000e-06
GCST007324_50	Adventurousness	5.000000e-08
GCST007325_185	General risk tolerance (MTAG)	1.000000e-08
GCST008550_14	Mental health study participation (completed survey)	7.000000e-09
GCST010988_244	Adult body size	9.000000e-10

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0004736	aspartate aminotransferase measurement
EFO:0004340	body mass index
EFO:1001488	influenza A (H1N1)
EFO:0007934	creatinine clearance measurement
EFO:0008579	risk-taking behaviour
EFO:0010130	health study participation

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

40 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases expression	4
Nickel	decreases expression	2
Cyclosporine	increases expression	2
aristolochic acid I	decreases expression	1
tungsten carbide	affects binding, decreases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
pirinixic acid	affects binding, increases activity, increases expression	1
trichostatin A	affects expression	1
beta-lapachone	decreases expression	1
sodium arsenite	increases expression	1
cobaltous chloride	increases expression	1
potassium chromate(VI)	decreases expression	1
nickel sulfate	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
monomethylarsonous acid	increases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	increases expression	1
jinfukang	affects cotreatment, decreases expression	1
NSC 689534	affects binding, increases expression	1
Temozolomide	increases expression	1
Arsenic Trioxide	affects cotreatment, increases expression	1
Acetaminophen	increases expression	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Cisplatin	affects cotreatment, decreases expression	1
Cobalt	affects binding, decreases expression	1
Copper	increases expression, affects binding	1
Doxorubicin	decreases expression	1
Estradiol	affects cotreatment, increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.